Muscular Dystrophy Drug

Muscular Dystrophy Drug

FILE - This Oct. 14, 2015, file photo shows the Food and Drug Administration campus in Silver Spring, Md. The FDA on Monday, Sept. 19, 2016, granted tentative approval to the first drug for muscular dystrophy, following an intense public campaign from patients and doctors who pushed for the largely unproven medication. The FDA cleared Sarepta Therapeutics’ Exondys 51 for a rare form of Duchenne muscular dystrophy, a deadly inherited disease that affects boys. (AP Photo/Andrew Harnik, File)

Use Information This content is intended for editorial use only.
For other uses, additional clearances may be required.

16253810980074
September 09, 2016 06:31:37 PM
September 19, 2016 06:51:40 PM
Andrew Harnik
AP
ASSOCIATED PRESS
OCT. 14, 2015, FILE PHOTO
4500 x 3000 2.63 MB
Food & Drug Administration campus
Muscular dystrophy, Medication, Diseases and conditions, Health, Diagnosis and treatment
FDA, Food & Drug Administration
Silver Spring, MARYLAND, UNITED STATES
NYBZ121
STF
AH RCL**DC**

This content is intended for editorial use only. For other uses, additional clearances may be required.

X

Message Box

Cancel
Ok
No
Yes